We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As the population aging in China is intensifying and drugs made in China are gradually replacing imported drugs, the market for hypolipidemic drugs in China is expected to grow continuously.